Windlas Biotech Ltd
Windlas Biotech Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #79 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Windlas Biotech has outperformed the industry in the last 11 quarters despite low overall volume growth in the Indian Pharma Market (IPM). Windlas Biotech refrains from providing explicit forward-looking guidance on growth or profits.
From Windlas Biotech Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Windlas Biotech has outperformed the industry in the last 11 quarters despite low overall volume growth in the Indian Pharma Market (IPM).
- Future growth drivers include:
- Expanding as a strong, quality-recognized player in contract manufacturing and Trade Generics.
- Dosage form expansion, notably into injectables.
- Expected rebound in suppressed volume growth due to increasing patient base, hospital beds, and income levels in India.
- The company refrains from giving exact forward-looking growth guidance but is optimistic about continued growth driven by quality, execution, and product portfolio expansion.
- Organic growth focused on oral solids with plans for inorganic expansion for other dosage forms.
2 more points from Windlas Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Windlas Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Plant-6 expansion is advancing well and is on track to commission within FY '26.
- Continued investments in quality, compliance, and capability expansion across dosage forms.
- Focus on organic growth via Plant-2 extension and Plant-6 for oral solids.
- Open to inorganic expansion to broaden portfolio, especially for new dosage forms, seeking good non-sick assets even at a premium.
- Investment in people emphasized through ESOP schemes to align talent with strategic growth.
2 more points from Windlas Biotech Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Windlas Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Windlas Biotech Ltd's call on order book
Create a free account to keep reading this call
Windlas Biotech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹238 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Windlas Biotech Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Windlas Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Windlas Biotech Ltd Q2 FY26 results?
Windlas Biotech has outperformed the industry in the last 11 quarters despite low overall volume growth in the Indian Pharma Market (IPM). Windlas Biotech refrains from providing explicit forward-looking guidance on growth or profits.
What is Windlas Biotech Ltd share price analysis?
Windlas Biotech Ltd currently shows a neutral. The stock trades at a P/E of 29.5 with a market cap of ₹1,959 Cr. Investors should review the full earnings analysis for detailed insights.
Is Windlas Biotech Ltd planning capital expenditure?
Plant-6 expansion is advancing well and is on track to commission within FY '26.
Keep Windlas Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.